The average one-year price target for Castle Biosciences (NasdaqGM:CSTL) has been revised to $43.99 / share. This is an increase of 14.24% from the prior estimate of $38.50 dated December 18, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $36.36 to a high of $54.60 / share. The average price target represents an increase of 10.97% from the latest reported closing price of $39.64 / share.
What is the Fund Sentiment?
There are 381 funds or institutions reporting positions in Castle Biosciences. This is an decrease of 8 owner(s) or 2.06% in the last quarter. Average portfolio weight of all funds dedicated to CSTL is 0.09%, an increase of 7.61%. Total shares owned by institutions decreased in the last three months by 1.35% to 32,456K shares. 
The put/call ratio of CSTL is 0.17, indicating a bullish outlook.
What are Other Shareholders Doing?
Principal Financial Group holds 1,794K shares representing 6.15% ownership of the company. In its prior filing, the firm reported owning 1,799K shares , representing a decrease of 0.26%. The firm decreased its portfolio allocation in CSTL by 51.32% over the last quarter.
Portolan Capital Management holds 1,515K shares representing 5.19% ownership of the company. In its prior filing, the firm reported owning 1,490K shares , representing an increase of 1.69%. The firm decreased its portfolio allocation in CSTL by 2.11% over the last quarter.
Nuveen holds 957K shares representing 3.28% ownership of the company. In its prior filing, the firm reported owning 1,073K shares , representing a decrease of 12.12%. The firm decreased its portfolio allocation in CSTL by 43.19% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 845K shares representing 2.89% ownership of the company. In its prior filing, the firm reported owning 831K shares , representing an increase of 1.67%. The firm decreased its portfolio allocation in CSTL by 7.45% over the last quarter.
PSBMX - SmallCap Fund (fka SmallCap Blend Fund) R-3 holds 830K shares representing 2.84% ownership of the company. In its prior filing, the firm reported owning 631K shares , representing an increase of 23.96%. The firm decreased its portfolio allocation in CSTL by 7.30% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
